Atara Biotherapeutics, Inc.: Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel) Commercialization Agreement with Pierre Fabre

Atara to Receive Additional USD 30 Million Upon European Commission (EC) Approval and Filing of Tab-cel Marketing Authorization Transfer to Pierre Fabre Responses Submitted to European Medicines

Related Keywords

California ,United States ,South San Francisco ,Pierre Fabre ,Eric Hyllengren ,Alex Chapman ,Eric Ducournau ,Pascal Touchon ,Atara Biotherapeutics Inc ,Linkedin ,Twitter ,European Commission ,Drug Administration ,Nasdaq ,Exchange Commission ,European Medicines Agency ,Securities Exchange ,Million Upon European Commission Ec Approval ,Receive Additional ,Upon European Commission ,Authorization Transfer ,Final Day ,Marketing Authorization Application ,Middle East ,Breakthrough Therapy Designation ,Priority Medicines ,Securities Act ,Securities Exchange Act ,Southern California ,Financial Condition ,Katara ,Iotherapeutics ,Eceive ,Dditional ,Ear ,Term ,Milestone ,Payment ,Under ,Pdated ,Tabelecleucel ,Ommercialization ,Agreement ,Pierre ,Sabre ,